Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of adagrasib monotherapy and adagrasib plus pembrolizumab in KRAS G12C-mutated advanced non-small cell lung cancer
ISRCTN13464104Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Mirati Therapeutics. Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN13464104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13464104.